• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alkermes plc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/21/25 4:15:15 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email
    8-K
    0001520262falseAlkermes plc.00015202622025-05-212025-05-21

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): May 21, 2025

    ALKERMES PUBLIC LIMITED COMPANY

    (Exact name of registrant as specified in its charter)

     

    Ireland

     

    001-35299

     

    98-1007018

    (State or other jurisdiction

     

    (Commission

     

    (IRS Employer

    of incorporation)

     

    File Number)

     

    Identification No.)

     

     

     

     

     

     

    Connaught House, 1 Burlington Road

    Dublin 4, Ireland D04 C5Y6

    (Address of principal executive offices)

     

    Registrant's telephone number, including area code: + 353-1-772-8000

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

     

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

     

    ☐

     

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Ordinary shares, $0.01 par value

     

    ALKS

     

    Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

     

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On May 21, 2025, at the 2025 annual general meeting of shareholders (the “Annual Meeting”) of Alkermes plc (the “Company”), the Company’s shareholders approved amendments to the Alkermes plc 2018 Stock Option and Incentive Plan to, among other things, increase the number of the Company’s ordinary shares authorized for issuance thereunder by 4,250,000 (the plan as so amended, the “2018 Plan”).

    The principal features of the 2018 Plan are summarized on pages 57-61 of the Company’s definitive proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Commission on April 7, 2025. That summary and the foregoing description are not intended to be complete and are qualified in their entirety by reference to the full text of the 2018 Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On May 21, 2025, the Company held its Annual Meeting. The final voting results for the Annual Meeting are as follows:

    1.
    By separate resolutions, shareholders elected the following directors, each to serve on the Company’s board of directors (the “Board”) for a one-year term until the Company’s 2026 annual general meeting of shareholders, with the votes cast as follows:

    For:

    Against:

    Abstain:

    Broker Non-Votes:

    Shane M. Cooke

    144,556,374

    704,862

    849,622

    8,347,962

    Richard B. Gaynor, M.D.

    142,882,295

    2,380,214

    848,349

    8,347,962

    Cato T. Laurencin, M.D., Ph.D.

    140,933,916

    4,231,803

    945,139

    8,347,962

    Nancy S. Lurker

    144,523,454

    731,150

    856,254

    8,347,962

    Brian P. McKeon

    144,418,372

    842,035

    850,451

    8,347,962

    Richard F. Pops

    141,115,166

    4,139,634

    856,058

    8,347,962

    Nancy L. Snyderman, M.D.

    138,701,039

    5,900,596

    1,509,223

    8,347,962

    Frank Anders Wilson

    144,341,353

    919,211

    850,294

    8,347,962

    Christopher I. Wright, M.D., Ph.D.

    140,630,049

    4,543,496

    937,313

    8,347,962

     

    2.
    Shareholders approved, in a non-binding, advisory vote, the compensation of the Company’s named executive officers, with the votes cast as follows: 143,326,743 votes for; 1,891,000 votes against; 893,115 votes abstaining; and 8,347,962 broker non-votes.
    3.
    Shareholders ratified, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company, and authorized, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm’s remuneration, with the votes cast as follows: 152,615,011 votes for; 990,750 votes against; and 853,059 votes abstaining.
    4.
    Shareholders approved the 2018 Plan, with the votes cast as follows: 126,994,261 votes for; 18,252,782 votes against; 863,815 votes abstaining; and 8,347,962 broker non-votes.
    5.
    Shareholders renewed Board authority to allot and issue shares under Irish law, with the votes cast as follows: 151,248,531 votes for; 2,359,603 votes against; and 850,686 votes abstaining.
    6.
    Shareholders renewed Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law, with the votes cast as follows: 149,705,078 votes for; 3,870,144 votes against; and 883,598 votes abstaining.

     

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    2


     

    EXHIBIT INDEX

     

    Exhibit No.

     

    Description

     

     

     

    10.1

     

    Alkermes plc 2018 Stock Option and Incentive Plan, as amended.

    104

     

    Cover page interactive data file (embedded within the Inline XBRL document).

     

     

    3


     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    ALKERMES PLC

     

     

    Date: May 21, 2025

    By:

     

    /s/ David J. Gaffin

     

     

     

    David J. Gaffin

     

     

     

    Secretary

     

    4


    Get the next $ALKS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    2/24/2026$45.00Outperform
    Wolfe Research
    11/11/2025$50.00Buy
    Truist
    9/26/2025$44.00Sector Perform → Outperform
    RBC Capital Mkts
    9/3/2025$44.00Overweight
    Wells Fargo
    7/15/2025$43.00Buy
    Goldman
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Finance (Interim PAO) Parisi Samuel Joseph converted options into 2,283 units of Ordinary Shares and covered exercise/tax liability with 672 units of Ordinary Shares, increasing direct ownership by 15% to 12,668 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    2/25/26 5:49:43 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Commercial Officer Nichols Christian Todd converted options into 6,407 units of Ordinary Shares and covered exercise/tax liability with 2,845 units of Ordinary Shares, increasing direct ownership by 3% to 112,762 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    2/25/26 5:48:29 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Operating Officer Jackson Blair Curtis converted options into 8,738 units of Ordinary Shares and covered exercise/tax liability with 3,880 units of Ordinary Shares, increasing direct ownership by 2% to 236,681 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    2/25/26 5:47:15 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    SEC Filings

    View All

    SEC Form 10-K filed by Alkermes plc

    10-K - Alkermes plc. (0001520262) (Filer)

    2/25/26 9:31:15 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    2/25/26 9:31:15 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    2/25/26 7:05:28 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

    Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. EST (1:00 p.m. GMT) today, to discuss these financial results and expectations and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at https://investor.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988

    2/25/26 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Announces CEO Succession Plan

    — Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes' Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue to Serve as Chairman of the Alkermes Board of Directors — Alkermes plc (NASDAQ:ALKS) (Alkermes) today announced that Richard Pops will retire from his role as Chief Executive Officer (CEO), effective July 31, 2026. Alkermes' Board of Directors (the Board) appointed Blair Jackson, Alkermes' current Executive Vice President, Chief Operating Officer, as the company's next CEO, effective Aug. 1,

    2/25/26 6:55:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

    Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 a.m. ET (2:10 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes' pipeli

    2/24/26 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Alkermes Plc with a new price target

    Wolfe Research initiated coverage of Alkermes Plc with a rating of Outperform and set a new price target of $45.00

    2/24/26 7:45:07 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Alkermes Plc with a new price target

    Truist initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $50.00

    11/11/25 8:03:02 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Plc upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Alkermes Plc from Sector Perform to Outperform and set a new price target of $44.00

    9/26/25 7:58:20 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Leadership Updates

    Live Leadership Updates

    View All

    Alkermes plc Announces CEO Succession Plan

    — Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes' Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue to Serve as Chairman of the Alkermes Board of Directors — Alkermes plc (NASDAQ:ALKS) (Alkermes) today announced that Richard Pops will retire from his role as Chief Executive Officer (CEO), effective July 31, 2026. Alkermes' Board of Directors (the Board) appointed Blair Jackson, Alkermes' current Executive Vice President, Chief Operating Officer, as the company's next CEO, effective Aug. 1,

    2/25/26 6:55:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Appoints Joshua Reed as Chief Financial Officer

    DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee. "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed.  Mr. Reed brings over 30 years of financial leadership experience, with a strong focu

    9/12/25 9:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

    DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern

    3/7/24 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Financials

    Live finance-specific insights

    View All

    Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

    Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. EST (1:00 p.m. GMT) today, to discuss these financial results and expectations and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at https://investor.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988

    2/25/26 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

    Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company's fourth quarter and year-end 2025 financial results. Management will also discuss financial expectations for 2026 and provide an update on the company. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visit

    2/11/26 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (NASDAQ:AVDL) ("Avadel") today announced that the companies have reached agreement on the terms of an increased recommended offer under which Alkermes will acquire Avadel (the "Acquisition") for total transaction consideration of up to $22.50 per share, consisting of $21.00 in cash and one (1) non-transferable contingent value right ("CVR") entitling holders to a potential additional ca

    11/19/25 6:00:00 AM ET
    $ALKS
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alkermes plc

    SC 13G - Alkermes plc. (0001520262) (Subject)

    11/14/24 1:22:34 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/12/24 1:28:21 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/8/24 10:46:38 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care